Corrigendum: Attenuation of Na/K-ATPase Mediated Oxidant Amplification With PNaKtide Ameliorates Experimental Uremic Cardiomyopathy

Authors

J LiuFollow
J Tian
M ChaudhryFollow
K Maxwell
Y Yan
Nader Abraham, New York Medical CollegeFollow
J Shapiro
Nader Abraham, New York Medical CollegeFollow
Z Xie
J Shapiro

DOI

10.1038/srep46893

Journal Title

Scientific Reports

First Page

46893

Document Type

Article

Publication Date

10-1-2017

Department

Medicine

Keywords

cardiomyopathies therapy, animal disease models, administration and dosage of enzyme activators and inhibitors, metabolism of heme oxygenase-1, C57BL inbred mice, protoporphyrins administration and dosage, reactive oxygen species metabolism, ROS, sodium-potassium-exchanging ATPase antagonists and inhibitors, treatment outcome, complications uremia

Disciplines

Medicine and Health Sciences

Abstract

This corrects the article DOI: 10.1038/srep34592.

Comments

Please see the work itself for the complete list of authors.

Recommended Citation

Liu, J., Tian, J., Chaudhry, M., Maxwell, K., Yan, Y., Abraham, N., Shapiro, J., Abraham, N., Xie, Z., & Shapiro, J. (2017). Corrigendum: Attenuation of Na/K-ATPase Mediated Oxidant Amplification With PNaKtide Ameliorates Experimental Uremic Cardiomyopathy. Scientific Reports, 7, 46893. https://doi.org/10.1038/srep46893

Publisher's Statement

Originally published in Scientific Reports 6:34592. The original material can be found here.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.